Trials / Completed
CompletedNCT02321748
Drug-Drug Interaction Study: ASP2151 and Montelukast
A Single-centre, Open-label, Randomised, Crossover, Drug-drug Interaction Study in Healthy Men to Investigate the Effect of a Single Dose of ASP2151 on the Pharmacokinetics of Montelukast
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Maruho Europe Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
CYP2C8 is involved in the metabolism of many drugs. So, it is important to assess in vivo the inhibitory effect of ASP2151 on that enzyme to determine any possible drug interactions. The aim of this trial is to investigate the potential for interaction of ASP2151 with the CYP2C8 probe substrate montelukast.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Montelukast | |
| DRUG | ASP2151 |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2014-12-22
- Last updated
- 2019-02-27
- Results posted
- 2019-01-14
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02321748. Inclusion in this directory is not an endorsement.